This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A randomized, double-blind, placebo controlled, mu...
Clinical trial

A randomized, double-blind, placebo controlled, multi-centre, phase IIA study to assess the effect on GERD symptoms, pharmacokinetics, safety and tolerability of four weeks treatment with AZD3355 65 mg bid as add-on treatment to a PPI in patients with an

Read time: 1 mins
Last updated:13th Sep 2006
To estimate the effect of AZD3355 65 mg twice daily (bid) as add-on treatment to a Proton Pump Inhibitor (PPI) on GERD symptoms in patients with an incomplete response to PPI treatment with respect to improvement of each of the patient reported symptoms: - a burning feeling behind the breastbone (heartburn) - unpleasant movement of material upwards from the stomach (regurgitation)
Category Value
Study start date 2006-09-13

View full details